Bereket 2005.

Methods	A longitudinally study of 16 months of methylphenidate treatment in newly diagnosed and untreated children
Participants	Number of participants screened: not stated Number of participants included: 72 Number of participants followed up: 14 Number of withdrawals: 58 Diagnosis of ADHD: DSM‐IV (subtypes: not stated) Age: mean 8.12 years, range 6.47‐10.32 IQ: none with mental retardation Sex: 10 males, 4 females Methylphenidate‐naïve: 100% Ethnicity: Turkish Country: Turkey Comorbidity: not stated Comedication: not stated Sociodemographics: not stated Inclusion criteria: ADHD according to DSM‐IV, confirmed by 2 child psychiatrists Exclusion criteria: Prematurity Low birth weight Any systemic disease
Interventions	Methylphenidate type: not stated Methylphenidate dosage: 0.75 mg/kg Administration schedule: not stated Duration of intervention: 16 months Treatment compliance: not stated
Outcomes	Non‐serious adverse events: Height measured with a Harpenden stadiometer. Performed every 4 months Weight measured "with minimal clothing". Performed every 4 months Height and weight measurements were transformed to SDs before the statistical analyses using normative data for Turkish children. BMI values were transformed to SDs according to data from Cole 2007
Notes	Sample calculation: no Ethics approval: approved by local ethics committee Funding: supported by a TUBITAK grant Vested interest/authors' affiliations: not stated Key conclusions of the study authors: prepubertal children with ADHD had normal height, weight, BMI, serum IGF‐I and IGFBP‐3 and thyroid functions. Methylphenidate treatment had no sustained effects on growth parameters, IGF‐I and IGFBP‐3 during the follow‐up period of this study. However, it caused a mild decrease in total and free T4, which may warrant further monitoring Supplemental information received through personal email correspondence with the authors in January 2014 (Bereket 2014 [pers comm])